Abstract Acetate supplementation attenuates neuroglial activation, increases histone and non-histone protein acetylation, reduces pro-inflammatory cytokine expression, and increases IL-4 transcription in rat models of neuroinflammation and Lyme's neuroborreliosis. Because eicosanoid signaling is involved in neuroinflammation, we measured the effect acetate treatment had on phospholipase, cyclooxygenase, and prostaglandin E 2 (PGE 2 ) levels in BV-2 microglia and primary astrocytes stimulated with lipopolysaccharide (LPS). In BV-2 microglia, we found that LPS increased the phosphorylation-state of cytosolic phospholipase A 2 (cPLA 2 ), reduced the levels of phospholipase C (PLC) b1, and increased the levels of cyclooxygenase (Cox)-1 and -2. Acetate treatment returned PLCb1 and Cox-1 levels to normal, attenuated the increase in Cox-2, but had no effect on cPLA 2 phosphorylation. In primary astrocytes, LPS increased the phosphorylation of cPLA 2 and increased the levels of Cox-1 and Cox-2. Acetate treatment in these cells reduced secretory PLA 2 IIA and PLCb1 levels as compared to LPS-treatment groups, reversed the increase in cPLA 2 phosphorylation, and returned Cox-1 levels to normal. Acetate treatment reduced PGE 2 release in astrocytes stimulated with LPS to control levels, but did not alter PGE 2 levels in BV-2 microglia. The amount of acetylated H3K9 bound to the promoter regions of Cox-1, Cox-2, IL-1b and NF-jB p65 genes, but not IL-4 in were increased in BV-2 microglia treated with acetate. These data suggest that acetate treatment can disrupt eicosanoid signaling in neuroglia that may, in part, be the result of altering gene expression due chromatin remodeling as a result of increasing H3K9 acetylation.
neuroglia activation in rat models of neuroinflammation [3] and Lyme neuroborreliosis [4] . Acetate supplementation further increases brain acetyl-CoA levels [3] , mitochondrial acetyl-CoA metabolism [5] , and alters brain histone acetylation in a time-and site-specific pattern in normal animals [6] and in rats subjected to neuroinflammation [7] . Further, long-term acetate supplementation reduces proinflammatory cytokine levels, and increases histone acetylation [7] . Increasing brain acetate metabolism with glyceryl triacetate also reverses LPS-induced increases in NF-jB p65 and IL-1b protein levels, and increases IL-4 protein levels in LPS-stimulated BV-2 microglia [8] and primary astrocyte cultures [9] . Acetate treatment transiently reduces LPS-induced MAPK p38 phosphorylation, and increases ERK1/2 phosphorylation in microglia cultures whereas in astrocyte cultures acetate completely attenuates LPS-induced MAPK p38 phosphorylation and reduces basal levels of phosphorylated ERK1/2. These studies suggest that acetate supplementation and increased acetyl-CoA metabolism acts to shift the brain cytokine balance toward a more anti-inflammatory state and potentially disrupts neuroglia MAPK and NF-jB signaling in a cell-type specific manner.
In pathological conditions, phospholipase activation and increases in eicosanoid signaling result in alterations in membrane permeability, the accumulation of free fatty acids and lipid peroxides, as well as the induction of many other inflammatory pathways [10, 11] . Phospholipases are a heterogeneous group of enzymes that metabolize membrane phospholipids. The physiological function of brain phospholipases include phospholipid turnover and metabolism, exocytosis, the removal of oxidized lipids, and are also involved in long-term potentiation, neural cell proliferation, and the release of neurotransmitters [12] [13] [14] . Cyclooxygenase (Cox)-1 and Cox-2 convert arachidonic acid, released by PLA 2 acting at the sn-2 position of membrane phospholipids, into prostaglandin (PG) H 2 which is the physiologic substrate for other terminal prostaglandin synthases' that form other biologically active prostaglandins [15] . Phospholipase A 2 (PLA 2 ) are classified into cytosolic PLA 2 (cPLA 2 ), secretory PLA 2 (sPLA 2 ), and calcium-independent PLA 2 (iPLA 2 ) depending on their requirement on calcium [13, 14] . The sPLA 2 group is divided into type I (pancreatic type) and type II (inflammatory type) [16] . The most well-studied of which is type IIA sPLA 2 expressed in most areas of rat brain and whose levels are elevated in inflammatory conditions like ischemia and endotoxic shock [17, 18] . Phospholipase C (PLC), based on structural characteristics are divided into PLCb, c, d, and e which cleaves the polar head group esterified at the sn-3 position of the phospholipid moiety and is commonly associated with modulating intracellular calcium and protein kinase C activation [19] . The suppression of PLCb1 by endotoxin is also associated with a disruption in purine-mediated neurotransmission that is involved in the switching macrophages from an M1 state to an M2-like phenotype [20] . Eicosanoid signaling is upregulated by lipopolysaccharide (LPS), pro-inflammatory cytokines interleukin (IL)-1b, IL-6 and tumor necrosis factor (TNF)-a, nuclear factor kappa-B (NF-jB), and mitogen-activated protein kinases (MAPK) p38, extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinases (JNK), all of which are all important mediators of neuroinflammation [11, 16, 21] . In this regard, cPLA 2 is activated by MAPK phosphorylation that results in its translocation to the plasma or nuclear membranes [22, 23] . Thus understanding how these signaling pathways are altered by acetate supplementation may provide insight into the mechanism by which it modulates neuroglia activation.
Histone acetylation is a common post-translational modification that is associated with changes in the gene expression due to increased accessibility of transcription machinery to chromatin [24] [25] [26] , increased flexibility of the DNA associated with the end of the nucleosomes [27] , and recruits proteins that facilitate downstream gene expression regulation [28] . The multitude of events and changes that take place during transcription are not due solely to changes in histone acetylation, but rather are the results of overlapping actions of several factors [29] and include the acetylation of non-histone transcription factors [30, 31] . Increases in histone acetylation is associated with anti-inflammatory outcomes in models of cerebral ischemia [32] , amyotrophic lateral sclerosis [33] , and reduces microglial activation in traumatic brain injury [34] . An increase in histone acetylation also reduces oxidative stress-induced apoptosis [35] , polyglutamine toxicity in a mouse motor neuron-neuroblastoma fusion cell line [36] and in Drosophila models of polyglutamine diseases [37] . All of which suggests that increasing histone acetylation may provide a potential therapeutic target into treat disorders associated with neuroinflammation [38] [39] [40] .
To expand on previous studies and to begin to determine how acetate supplementation attenuates inflammatory neuroglia activation, we quantified the effect of acetate treatment had on the levels of enzymes involved in eicosanoid signaling and PGE 2 release in astrocytes and BV-2 microglial cell cultures stimulated with LPS. Further, using chromatin immunoprecipitation, we measured the effect treatment had on H3K9 binding to the promoters of the genes coding for Cox-1, Cox-2, IL-1b, IL-4 and NF-jB p65 in BV-2 microglia. Acetate reduced sPLA 2 IIA, PLCb1 and cPLA 2 phosphorylation and PGE 2 release in astrocytes, but only Cox-2 protein levels in BV-2 microglia, while the binding affinity of acetylated H3K9 towards Cox-1 and 2, IL-1b, and NF-jB p65, but not the IL-4 promoter regions was increased in BV-2 microglia. These data suggest that acetate treatment can disrupt eicosanoid signaling in neuroglia, which may contribute to the antiinflammatory properties found by increasing brain acetylCoA metabolism.
Materials and Methods
Reagents LPS (Escherichia coli 055:B5) and proteinase K were purchased from Sigma (St. Louis, MO). Antibodies against PLCb1, c1, d1, cPLA 2 were from Santa Cruz Biotechnology Inc. (Santa Cruz, CA), while antibodies against Cox-1, Cox-2 and sPLA 2 IIA, and prostaglandin screening EIA kits were purchased from Cayman Chemical Company (Ann Arbor, MI). A goat anti-rabbit horse radish peroxidase-linked secondary antibody was purchased from Bio-Rad Laboratories (Hercules CA), and DMEM-F-12 media, fetal bovine serum and RNAse A was from Invitrogen (Grand Island, NY). All buffering reagents and other chemicals were purchased from EMD Biosciences (Gibbstown, NJ). A chromatin immunoprecipitation assay kit, antibodies toward acetylated H3K9, and normal rabbit IgG were purchased from Millipore (Billerica, MA). A QIAquick PCR purification kit was purchased from Qiagen (Valencia, CA) and protein A and protein G magnetic beads were purchased from Invitrogen (Grand Island, NY). FastStart Universal SYBR Green Master and complete EDTA-free protease inhibitor cocktail tablets were purchased from Roche Applied Science (Indianapolis, IN) while all chromatin immunoprecipitation primers (Table 1) were purchased from Integrated DNA Technologies (Coraville, IA).
Cell Cultures
Primary astrocyte cultures were prepared from C57BL/6 mouse brains as described previously [41] and BV-2 cells were cultures as previously described [8] . All procedures involving the use of mice were conducted in accordance with an animal care and protocol approved by the UND ACUC (Protocol # 1004-1). Prior to stimulating the cells (3 h), the culture media were changed to serum-free media. At this time, plates were divided into 4 different groups; group one was treated with 12 mM sodium chloride (NaCl) as a control group, group two was treated with 12 mM sodium acetate, group three was treated with both 6.25 ng/ml LPS and 12 mM NaCl, and the fourth group was treated with both 6.25 ng/ml LPS and 12 mM sodium acetate (n = 6 per group). The sodium acetate concentration used in this study is the same as that previous reported in vitro, which does not result in cell death over a 24 h exposure period, maximizes cellular levels of acetyl-CoA, and is controlled using equal concentrations of sodium chloride [8, 9] . After 4 h of treatment, the media were collected and stored at -20°C, and the cells were lysed in ice cold RIPA lysis buffer (pH 8.0) containing 150 mM sodium chloride, Triton X-100, 0.5 % sodium deoxycholate, 0.1 % sodium dodecyl sulphate, 50 mM. Samples used for Western blot analysis were aliquoted into 100-lL units and stored at -80°C.
Western Blot Analysis
The Western blot analysis and protein quantification was performed as described previously [8, 9] . The antibody concentrations used for phosphorylated cPLA 2 , cPLA 2 , sPLA 2 IIA, PLCb1, PLCc1, PLCd1, Cox-1 and Cox-2 were 1:250, 1:500, 1:500, 1:250, 1:350, 1:350, 1:1,000, and 1:1,000, respectively. All Western blot data are expressed as the ratio of the optical density of the respective protein normalized to the optical density of a-tubulin. The phosphorylation ration of cPLA 2 was calculated by normalizing the optical density of phosphorylated cPLA 2 to the optical density of total cPLA 2 . Image analysis was performed using a UVP EpiChemi 3 Imaging system equipped with VisionWorks LP image acquisition and analysis software (Ver. 6.3.1, Upland, CA).
Chromatin Immunoprecipitation
After treating the cells for 4 h, cross linking was performed using 1 % paraformaldehyde at room temperature for 10 min, followed by 0.125 M glycine at room temperature for 5 min. The cells were then washed once with phosphate-buffered saline (PBS, pH 7.4) containing 137 mM NaCl, 2.7 mM KCl, 10 mM Na 2 HPO 4 , 2 mM KH 2 PO 4 prior to adding 0.2 % trypsin and incubating at 37°C for 5 min (5 % carbon dioxide atmosphere). Trypsin was neutralized with fetal bovine serum. Sample used for chromatin immunoprecipitation were suspended in SDS lysis buffer (1 % SDS, 10 mM EDTA, 50 mM Tris, pH 8.1) containing a protease inhibitor cocktail. Cells in SDS lysis buffer were extracted using sonication then centrifuged at 15,0009g for 30 min at 4°C to remove cellular debris. Immunoprecipitation was performed for 3 h at 4°C using 7 lg of acetylated H3K9 antibody, normal rabbit IgG, protein A, and protein G magnetic beads. The magnetic beads were washed four times with low-salt wash buffer (0.1 % SDS, 1 % Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.1, 150 mM NaCl), once with highsalt wash buffer (0.1 % SDS, 1 % Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.1, 500 mM NaCl), and finally with TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0). The samples were then eluted off the beads at 65°C for 15 min using elution buffer (50 mM Tris-HCl, 10 mM EDTA, 1 % SDS, pH 8.0). Samples were incubated at 65°C overnight to reverse the crosslinks, then incubated with RNAse A (0.2 lg/ml) for 2 h at 37°C, and with proteinase K (0.2 lg/ml) for 2 h at 55°C. One lg of the chromatin immunoprecipitation end product, with 1 lg of forward and reverse primers, 10 ll SYBR green, and 8 ll of nuclease-free water were used for quantitative real-time polymerase chain reaction (qrt-PCR).
Prostaglandin Quantification
An enzyme linked immunoassay was used to quantify PGE 2 release into the media of BV-2 microglia and primary astrocyte cell cultures. The analysis was performed according the manufacturer's instructions and the final absorbance was measured at 405 nm using a Labsystem MultiSkan Plus plate reader (Fisher Scientific).
Statistical Analysis
A one-way Analysis of Variance (ANOVA) followed by Tukey's post hoc test using GraphPad InStat software (Version 3.06 for Windows, San Diego, CA) was used to calculate statistical significance of the data. All results are expressed as means ± SD with the statistical significance set at p B 0.05.
Results

Phospholipase Levels in BV-2 Microglia
To determine the effect acetate treatment had on phospholipase levels, we measured cPLA 2 phosphorylation and the total protein levels of cPLA 2 , sPLA 2 IIA and PLC using Western blot analysis form whole cell BV-2 lysates. Protein bands corresponding to cPLA 2 , phosphorylated cPLA 2 , sPLA 2 IIA, PLCb1, PLCc1, PLCd1, and a-tubulin were detected at the molecular weight of 85, 85, 18, 150, 155, 85, and 50 kDa, respectively (Fig. 1a) . The protein levels of total cPLA 2 were not different between groups (Fig. 1b) , whereas LPS increased phosphorylated cPLA 2 by 1.5-fold which was not altered by acetate treatment (Fig. 1c) . The protein levels of sPLA 2 IIA, PLCc1 and PLCd1 were not altered by either LPS or acetate treatment (Fig. 1d, f, g ). By contrast, LPS decreased PLCb1 by twofold which was reversed to control levels with acetate treatment (Fig. 1e ).
Phospholipase Levels in Primary Astrocytes
To determine the effect acetate treatment had on phospholipase levels in LPS-treated astrocytes, we performed Western blot analysis on whole cell lysates as described above. The protein levels of total cPLA 2 were not different between groups (Fig. 2b) , however LPS increased phosphorylated cPLA 2 by twofold which was returned to control levels by acetate treatment but remained significantly elevated compared to cells treated with acetate alone (Fig. 2c) . Acetate treatment decreased the protein levels of sPLA 2 IIA and PLCb1 by 20 % in the presence of LPS (Fig. 2d, e) . PLCc1 and PLCd1 protein levels were not altered by either LPS or acetate treatment (Fig. 2f, g ).
Cox-1 and 2 Levels in Primary Astrocyte and BV-2 Microglia Cultures
Because cyclooxygenases are the rate-limiting step in the release of eicosanoids, we measured the effect of acetate treatment on Cox-1 and Cox-2 protein levels in BV-2 microglia and primary astrocytes cultures. Using whole cell lysates for Western blot analysis, Cox-1, Cox-2, and atubulin were detected as protein bands corresponding to molecular weights of 70, 72, and 50 kDa, respectively (Fig. 3a) . In BV-2 microglia cultures, LPS increased Cox-1 levels by 1.5-fold which was reversed to control levels with acetate treatment (Fig. 3b) . Cox-2 levels were increased fourfold and partially attenuated with acetate treatment (Fig. 3c) . In astrocyte cultures, LPS increased the protein levels of Cox-1 by 1.5-fold which was reversed to control levels with acetate treatment (Fig. 3d) . Cox-2 levels were increase in astrocyte cultures treated with LPS by 2.9-fold, but was not altered by acetate treatment (Fig. 3e) .
Prostaglandin E 2 Levels in BV-2 Microglia and Primary Astrocyte Cultures
Having demonstrated the ability of acetate treatment to alter cPLA 2 phosphorylation, sPLA 2 IIA, Cox-1 and Cox-2 protein levels, we proceeded to determine the effect acetate treatment had PGE 2 release using an enzyme immunoassay. In BV-2 microglia, PGE 2 levels were not altered by either LPS or acetate treatment (Fig. 4a ) despite significant changes in Cox-1 and Cox-2 (Fig. 3b, c) . On the other hand, LPS increased PGE 2 levels by fourfold in astrocyte cultures which was completely reversed to control levels with acetate treatment (Fig. 4b) .
Binding of Acetylated H3K9 to Promoter Regions of Genes Involved in Inflammation
Acetate treatment increases H3K9 acetylation in vivo [6, 7] and reverses LPS-induced increase in NF-jB p65 protein but not IL-1b mRNA, and increases IL-4 expression in vitro [8, 9] . Because changes in histone acetylation are associated with alterations in gene expression [42, 43] , we measured the enrichment of acetylated H3K9 to promoters of ptgs1, ptgs2 (coding for Cox-1 and Cox-2, respectively), p65, il4 (Il-4) and il1b (IL-1b) genes in BV-2 microglia treated with acetate. Five different primer sets were prepared for each gene with the exception of il1b where four primer sets were used. The primers were designed to span different genomic stretches ranging between -750 base pairs and ?1,000 base pairs in relation to the transcription start site (Table 1) . Acetate treatment increased acetylated H3K9 bound to three COX-1 gene sequences: between -393 and -157, -129 and ?112, and ?668 and ?869 (Fig. 5a ) and one COX-2 gene sequence: between ?750 and ?971 (Fig. 5b) . In addition, acetate treatment was found to increase acetylated H3K9 bound to three p65 gene sequences: between -743 and -557, between -518 and -336, and between ?146 and ?272 (Fig. 5c) , and three IL-1b gene sequences: between -450 and -229, between -125 and ?89, and between ?550 and ?794 (Fig. 5e) . Acetate treatment did not alter the binding of acetylated H3K9 to the IL-4 promoter region (Fig. 5d) . LPS treatment reduced the levels of acetylated H3K9 bound to the promoter region of COX-1 between -393 and -157 as compared to sodium chloride controls. The levels of acetylated H3K9 bound to promoter were also reduced in Fig. 1 regions 2 and 3 (COX-1), region 5 (COX-2), regions 1 and 2 (p65), and regions 2, 3, and 4 (IL-1b) compared to cells treated with sodium acetate (Fig. 5a , b, c, e respectively).
Discussion
In LPS-stimulated BV-2 microglia [8] and primary astrocyte cultures [9] , acetate treatment decreases LPS-induced pro-inflammatory cytokines, MAPK signaling and NF-KB p65 protein level and phosphorylation in neuroglial cell type-distinct patterns. Because phospholipase activation and eicosanoids are involved in neuroinflammation that is modulated by inflammatory cytokines and MAPK and NFjB signaling [22, 23, 44, 45] and is reduced by acetate treatment [8, 9] , we tested whether acetate can alter the levels phospholipases, Cox, and PGE 2 release in BV-2 microglia and astrocyte cultures. Further, because H3K9 acetylation alters gene expression [42, 43] , and acetate treatment induces global histone hyperacetylation [7, 8] , we measured the enrichment levels of acetylated H3K9 bound to the promoters of the genes coding for Cox-1, Cox-2, IL-1b, IL-4 and NF-jB p65 in BV-2 microglia. These data suggest that acetate treatment can disrupt eicosanoid signaling in astrocytes, and alters the levels of enzymes involved in eicosanoid release in microglia. The neuroglial cell type-distinct effects of acetate on eicosanoid signaling, and possible chromatin remodeling, may contribute to the distinct anti-inflammatory response found with acetate supplementation both in vivo [3, 4] and in vitro [8, 9] . The findings that acetate treatment can modulate eicosanoid signaling are important because of the involvement of eicosanoids in a number of diseases. Prostaglandins are a class of eicosanoids that are formed downstream to the release of arachidonic acid. PGE 2 release and cPLA 2 and Cox expression are increased after LPS and IL-1b injection, aging and brain trauma [44, 46] , Alzheimer's [47] , and Parkinson's [48] diseases, among many other neuroinflammatory and degenerative conditions [49] . Pharmacological inhibition of cPLA 2 , cyclooxygenases and PGE 2 release is associated with antiinflammatory and neuroprotective properties and improved cognitive functions in aging [50] , and animal models of Alzheimer's disease [51] , traumatic brain injury [52] , ischemia [53] and amyotrophic lateral sclerosis [54] . Drugs like corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs) target primarily the enzymes involved in eicosanoids release. The potential of acetate treatment to disrupt eicosanoid signaling is promising given the possibility of acetate selectively disrupts this pathway only in certain cell types, unlike global cPLA 2 and Cox inhibitors that deprive many cell types from the physiological functions of eicosanoid signaling. In this regard, it will be interesting to evaluate whether acetate treatment reduces the side effects associated with NSAIDs like hyperacidity and alteration of blood coagulation, and the side effects associated with glucocorticoids like compromising immunity, blood sugar and blood pressure regulation. Acetate treatment may potentially prove to be more effective compared to current NSAID therapy given its additive effect on other signaling pathways like MAPK, NF-jB and inflammatory cytokines [8, 9] . Acetate supplementation increases the acetylation-state of brain H3K9, H4K8 and H4K16, but not H3K14, H4K5 or H4K16 in normal rats [6] and is similar in a rat model of neuroinflammation [7] . LPS reduces acetylated H3K9 twofold and this is reversed with acetate supplementation to a hyperacetylated-state in vivo [7] which is reproducible in BV-2 microglia in vivo [8] . Further, acetate increases H3K9 acetylation in astrocytes, but LPS itself does not reduce acetylated H3K9 in this cell type as found in vivo [9] . Because H3K9 acetylation is implicated in neuroinflammation and neuroglial activation [34, 55, 56] , we chose to focus only on H3K9 in this study. For these reasons chromatin immunoprecipitation was performed in BV-2 microglia cultures, where H3K9 acetylation is altered by both LPS and acetate treatment. This study demonstrates the effect of acetate treatment on the protein levels of Cox-1 and 2 which were increased with LPS challenge and reduced upon acetate treatment. Acetate treatment also reverses LPS-induced IL-1b and NF-jB p65 protein levels, and upregulates IL-4 expression in both LPS-stimulated BV-2 microglia [8] and primary astrocyte cultures [9] . In an attempt to determine whether acetate-induced H3K9 hyperacetylation is involved in the regulation of these inflammatory mediators at the gene levels, we measured the binding of acetylated H3K9 to the promoter regions of these genes of interest. Chromatin immunoprecipitation analysis showed that acetate treatment increased the binding of acetylated H3K9 to the promoters of each of these genes with the exception of IL-4, suggesting that acetate-induced H3K9 acetylation may potentially modulate the expression of these specific genes. Acetylated H3K9 is conventionally associated with enhanced gene expression [42, 43] . Of the five genes analyzed using chromatin immunoprecipitation, acetate increases IL-4 transcription, did not alter IL-1b mRNA, and decreases NF-jB p65, Cox-1 and 2 protein levels, while acetylated H3K9 bound to the promoter regions of each of these genes except IL-4 was increased. Because acetate treatment induces histone acetylation changes other than H3K9; including H4K8 or H4K16 [6, 7] , warrants more experiments to evaluate the involvement of other histones in mediating changes in pro-inflammatory gene expression. Alternatively, acetate treatment-mediated gene expression changes can possibly be linked to acetylation of non-histone transcription factors disrupting in parallel other inflammatory signaling pathways [8] .
Of interest, acetate reduces sPLA 2 IIA and LPS-induced cPLA 2 phosphorylation in astrocytes and not BV-2 microglia. By contrast, acetate treatment attenuates LPSinduced Cox-2 levels in BV-2 microglia and not in astrocytes. Because cPLA 2 is a substrate for phosphorylation by MAPK p38 [22, 23] and ERK [22] , both of which are inhibited by acetate treatment in astrocytes and not BV-2 microglia, suggests that acetate treatment reverses cPLA 2 phosphorylation primarily by reducing MAPK p38 and ERK activity. This is supported by studies showing that pro-inflammatory cytokines IL-1b and TNF-a increase cPLA 2 phosphorylation and sPLA 2 IIA expression and activity [45, 57, 58] that is reduced with the administration of TNF-a antibodies and IL-1 receptor antagonists [21] . Similarly, TNF-a enhances Cox-2 promoter activity [59] . It is therefore possible that acetate treatment may reduce cPLA 2 phosphorylation, sPLA 2 IIA and Cox-2 expression by reducing LPS-induced TNF-a and IL-1b expression. Although generally plausible, this does not explain why acetate treatment did not reduce cPLA 2 phosphorylation in BV-2 microglia and Cox-2 levels in astrocytes found in this study.
Distinct neuroglial cell type responses to acetate treatment include the complete reversal of LPS-induced astrocyte activation in vivo, while only partially attenuating microglia activation [3] . In LPS-stimulated BV-2 microglia, acetate treatment transiently reduces LPS-induced MAPK p38 and JNK phosphorylation and increases ERK1/ 2 phosphorylation [8] . By contrast, in LPS-stimulated primary astrocyte cultures, acetate treatment completely reduces MAPK p38 activation and decreases basal levels of phosphorylated ERK1/2 [9] . These data suggest that the complete inhibition of cPLA 2 phosphorylation and PGE 2 release in the astrocyte but not in BV-2 microglia may be involved in the attenuation of reactive astrogliosis and partial attenuation of microglia activation found in vivo [3] . Thus it will be important to determine the role that a reduction in astrocytes derived prostaglandin release has in disrupting neuroglia communication both in vivo and in mixed microglia and astrocytes cultures in vitro.
In conclusion, acetate treatment can disrupt eicosanoid signaling in LPS-stimulated primary astrocyte, and alters the levels of enzymes involved in eicosanoids release in microglia. Acetate treatment also induces increases in the binding of acetylated H3K9 to the promoters of certain inflammatory genes which may potentially be involved in chromatin remodeling and changes in inflammatory gene expression.
